Literature DB >> 8602634

Acquired free protein S deficiency associated with multiple myeloma: a case report.

S R Deitcher1, J K Erban, S A Limentani.   

Abstract

Investigation of recurrent venous thromboembolic events in a 46-year-old man with progressive IgG kappa (total serum IgG, 74.3 mg/ml) multiple myeloma revealed profound reductions in free protein S (PS) antigen (<0.l U/ml) and PS activity (0.33 U/ml). Total PS antigen, protein C, antithrombin III, and C4b-binding protein levels were within normal limits. The patient had no family history suggestive of a congenital PS deficiency and no history of thrombosis predating the diagnosis of his plasma cell dyscrasia. Patient IgG was isolated from serum using a protein A-sepharose affinity column and characterized. PS-dependent clotting assays (Staclot Protein S, Diagnostica Stago, Asnieres sur-Seine, France) performed on normal pooled plasma mixed with dilutions of patient IgG (0.0-33.0 mg/ml) revealed a dose-dependent neutralization of PS activity by 43%. Total and free PS antigen levels were measured using Laurell rocket electroimmunodiffusion (Assera-Plate Protein S, Diagnostica Stago), which revealed a similar dose-dependent reduction in free PS antigen but preserved normal total PS antigen. Free PS antigen was reduced by 77% to 0.23 U/ml using an IgG concentration (16.5 mg/ml) less than one-fourth of that of the patient at time of serum collection. Specific binding of the patient IgG to commercially available purified human PS was demonstrated by Western immunoblot analysis. Whereas acquired free PS deficiency has been previously reported in association with nephrotic syndrome, inflammatory bowel disease, HIV infection, and varicella infection, this is the first reported case of a hypercoagulable syndrome associated with acquired free PS deficiency and multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8602634     DOI: 10.1002/(SICI)1096-8652(199604)51:4<319::AID-AJH12>3.0.CO;2-9

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  Decreased protein S activity is related to the disease activity of Behcet's disease.

Authors:  Seong Ryul Kwon; Mie Jin Lim; Shin Goo Park; Yeon Sook Moon; Won Park
Journal:  Rheumatol Int       Date:  2006-09-13       Impact factor: 2.631

Review 2.  Thrombotic complications in multiple myeloma: a report of three cases and review of the literature.

Authors:  Yonal Ipek; Hindilerden Fehmi; Besisik-Kalayoglu Sevgi; Sargin Deniz
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

3.  Protein S: a Multifunctional Anticoagulant.

Authors:  A'drianne Dorsey; Vijaya Satish Pilli; Howard Fried; Rinku Majumder
Journal:  Biomed Res Clin Pract       Date:  2017-11-20

4.  Predictors of venous thromboembolism in patients with advanced common solid cancers.

Authors:  Isaac E Hall; Martin S Andersen; Harlan M Krumholz; Cary P Gross
Journal:  J Cancer Epidemiol       Date:  2010-02-16

Review 5.  Cancer and thrombosis: mechanisms and treatment.

Authors:  Steven R Deitcher
Journal:  J Thromb Thrombolysis       Date:  2003 Aug-Oct       Impact factor: 2.300

Review 6.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.